Dimensional Fund Advisors LP Lowers Stock Position in Health Catalyst, Inc. $HCAT

Dimensional Fund Advisors LP cut its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 24.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,234,870 shares of the company’s stock after selling 406,658 shares during the period. Dimensional Fund Advisors LP’s holdings in Health Catalyst were worth $1,568,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC bought a new position in Health Catalyst in the fourth quarter worth approximately $25,000. Cresset Asset Management LLC purchased a new stake in shares of Health Catalyst during the 2nd quarter worth $39,000. Focus Partners Wealth bought a new stake in Health Catalyst during the first quarter valued at about $46,000. BNP Paribas Financial Markets boosted its position in Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock valued at $47,000 after purchasing an additional 6,832 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Health Catalyst in the fourth quarter valued at about $64,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $1.85 on Friday. The stock has a market capitalization of $139.23 million, a price-to-earnings ratio of -0.50 and a beta of 1.55. The stock has a 50-day moving average of $2.00 and a 200 day moving average of $1.69. The company has a current ratio of 2.70, a quick ratio of 1.69 and a debt-to-equity ratio of 1.51. Health Catalyst, Inc. has a twelve month low of $0.96 and a twelve month high of $3.80.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The company had revenue of $70.49 million for the quarter, compared to analyst estimates of $69.09 million. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%. Sell-side analysts anticipate that Health Catalyst, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Ratings Changes

HCAT has been the subject of a number of analyst reports. Citigroup decreased their target price on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday. Stephens reduced their price target on Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Canaccord Genuity Group increased their price objective on Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings raised Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Finally, Wells Fargo & Company dropped their target price on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a research note on Thursday. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Health Catalyst presently has an average rating of “Hold” and a consensus target price of $2.93.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.